69 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
. Travere also completed regulatory engagement on focal segmental glomerulosclerosis (FSGS) in which the FDA communicated that the Phase 3 DUPLEX study
425
e3fvsw4ru8vx0gqp11
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
ioyz7o3xcerl w6
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
pg7o0em fztx
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-2.1
ow8b3t qqlz174vspsa
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.2
brits5l5 kf3veani8l
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-10.1
cv4h98132yueo3juiz
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
SC TO-T
EX-99
l00b9wd1
31 Aug 20
Third party tender offer statement
8:46am
SC TO-C
EX-2.1
kolhthd1ie1ud7ntgtf
10 Aug 20
Information about tender offer
9:50pm
8-K
EX-2.1
5gbbn
10 Aug 20
Tender and Support Agreement
9:48pm